ACG-701 (formerly ARV-1801) is a version of sodium fusidate. It is a compound that is used to treat methicillin-resistant Staphylococcus aureus, a cause of some CF lung infections, and may also decrease inflammation and mucus production. Sodium fusidate has been used in Europe, but it has never been approved in the U.S. This potential treatment comes in oral tablet form.

Status

A phase 2 study to test the safety and effectiveness of ACG-701 in people with CF is planned.

Sponsor

This program is sponsored by Aceragen, Inc. and partially funded by the Cystic Fibrosis Foundation. It is being conducted through the Therapeutics Development Network.